BioSpace News Archive

CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors.

Diverse Biotech, Inc. www.diversebiotech.com announced today that it has finalized a strategic transaction with Enveric Biosciences to license exclusive worldwide development and commercialization rights for five novel compounds to address the adverse side effects of cancer treatments.

BrightInsight, Inc., provider of the leading global regulated digital health platform for biopharma and medtech, announced today the launch of the AstraZeneca AMAZE™ Disease Management Platform built on the BrightInsight™ Platform

VolitionRx Limited announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2020, in addition to providing a business update.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today it is joining forces with AccessHope™ to offer a world-class service experience to people who use Galleri™, GRAIL’s first-of-kind multi-cancer early detection blood test.

7D Surgical, a Toronto based medical device company developing advanced, cutting-edge optical and machine-vision technologies for surgical navigation, announced today that it has successfully launched its FLASH™ Navigation System into Germany and Switzerland, with multiple units already placed and over 30 spinal procedures completed since the start of the new year.

Rapid Micro Biosystems, Inc., the leading provider of data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, today announced the completion of an $81 million equity financing.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the selection of CB5138-3 as its lead candidate for advancement into IND-enabling activities.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders.

The American Cancer Society is a global grassroots force of nearly 2 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer.